Healthcare >> CEO Interviews >> January 10, 2001
JEAN-JACQUES BIENAIM is Chairman, Chief Executive Officer and President
of Genencor International, Inc. Mr. Bienaim joined Genencor in November
2002 from SangStat Medical Corporation where he served as Chairman,
Chief Executive Officer and President. Since 1998 he managed SangStat's
growth from a $4 million company to over $100 million and guided the
company to profitability. A biotechnology company focused on immunology,
SangStat has two drugs on the market and two more in advanced stages of
clinical development. Before joining SangStat, Mr. Bienaim was Senior
Vice President of Corporate Marketing and Business Development at Rhone-
Poulenc Rorer Pharmaceuticals (now Aventis), a $6 billion business,
where he was responsible for worldwide marketing, medical affairs
strategy, licensing and business development. Prior to that position,
Mr. Bienaim was Vice President and General Manager of RPR's advanced
therapeutic and oncology division. Other highlights of his career
include five years at Genentech where he was Director of Marketing,
Cardiopulmonary Products. Mr. Bienaim is a member of the Board of
Directors of Aerogen Inc. and the Fox Chase Cancer Center in
Philadelphia. He received an MBA from the Wharton School at the
University of Pennsylvania and an undergraduate degree in Economics from
the Ecole Superieure de Commerce de Paris. Profile
company?
Mr. Bienaime: We have continued to grow since I last spoke to you
several months ago, but we have changed the
